Related Experiment Video
Updated: Jun 24, 2026
08:16
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
Published on: June 17, 2015
Huperzine A for vascular dementia.
Zilong Hao1, Ming Liu, Zhiqin Liu
1Department of Neurology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan Province, China, 610041.
The Cochrane Database of Systematic Reviews
|April 17, 2009
Summary
Huperzine A, a herbal treatment, shows no convincing evidence for improving vascular dementia (VaD) based on a small trial. Further research is needed to determine its efficacy and safety in VaD patients.
Area of Science:
- Neurology
- Pharmacology
- Herbal Medicine
Background:
- Huperzine A is a herbal medicine explored as a potential treatment for vascular dementia (VaD).
- Its use as an alternative therapy for VaD is prevalent in China.
Purpose of the Study:
- To evaluate the effectiveness and safety of Huperzine A for patients diagnosed with vascular dementia.
- To synthesize evidence from randomized controlled trials on Huperzine A's impact on VaD.
Main Methods:
- A comprehensive search of multiple databases including Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS, and Chinese databases was conducted.
- Eligible studies included randomized controlled trials comparing Huperzine A with placebo in vascular dementia patients.
- Data extraction and quality assessment were performed independently by two review authors.
Main Results:
- One small trial with 14 participants was included in the review.
- No significant improvement in cognitive function (measured by MMSE) was observed with Huperzine A compared to placebo (WMD 2.40; 95% CI -4.78 to 9.58).
- While no deaths were reported, wide confidence intervals suggest potential for both benefits and harms, indicating uncertainty in the results.
Conclusions:
- The current evidence from one small trial is insufficient to support the use of Huperzine A for vascular dementia.
- Further high-quality research is warranted to establish the true value of Huperzine A in treating VaD.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...